What is Zacks Research’s Forecast for FOLD Q1 Earnings?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Zacks Research issued their Q1 2025 earnings per share (EPS) estimates for shares of Amicus Therapeutics in a report issued on Tuesday, April 1st. Zacks Research analyst R. Department forecasts that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Amicus Therapeutics’ current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics’ Q3 2026 earnings at $0.11 EPS.

A number of other equities analysts also recently issued reports on FOLD. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Wells Fargo & Company reduced their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $7.99 on Thursday. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics has a 12 month low of $7.85 and a 12 month high of $12.65. The firm’s fifty day simple moving average is $9.19 and its two-hundred day simple moving average is $9.90. The stock has a market capitalization of $2.45 billion, a P/E ratio of -44.39, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of FOLD. Virtus Fund Advisers LLC bought a new stake in Amicus Therapeutics during the 4th quarter valued at $29,000. Covestor Ltd boosted its holdings in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 2,312 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Amicus Therapeutics in the third quarter worth about $55,000. GF Fund Management CO. LTD. purchased a new position in Amicus Therapeutics during the 4th quarter valued at about $59,000. Finally, R Squared Ltd bought a new position in Amicus Therapeutics during the 4th quarter valued at approximately $79,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.